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Abstract Iron balance is tightly linked to inflamma-
tion and it has been demonstrated that many proteins
involved in cellular iron management are up- or down-
regulated by inflammatory stimuli, ultimately leading
to iron retention in the reticuloendothelial system.
Ferroportin is a key player in maintenance of correct
iron homeostasis, because it is the only known
mammalian cellular iron exporter. In this work we
show that incubation of THP-1 monocytes/macro-
phages with lactoferrin prevents the LPS-induced
decrease of ferroportin by reducing secretion of IL-6.
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Introduction
The importance of iron for all eukaryotes, and partic-
ularly for humans, is widely recognized. Iron is essential
for transport, storage and activation of oxygen, for
electron transfer and many other metabolic processes. It
is not surprising that defects affecting iron metabolism
genes cause severe pathologies in man. Iron homeosta-
sis is also tightly linked to inflammation and to response
to pathogens; macrophages are specialized cells that
play a key role in both these processes (Cairo et al.
2011). Iron retention in the reticulo-endothelial system
is viewed as the main response of body iron homeostasis
to inflammation and it is regarded as a host’s attempt to
withhold iron from the invading pathogens. On the other
hand, if not properly controlled, this situation can lead to
the anemia of inflammation. As a matter of fact, it has
been shown that the expression of many proteins
involved in cellular iron management by macrophages
varies in response to inflammatory stimuli or in the
presence of pathogens.
Ferroportin (SLC40A1, initially also named MTP1
or IREG1) is the only iron exporter identified in
mammalian cells, with a key role in maintenance of
correct iron balance in the body. Ferroportin was
initially localized on the basolateral membrane in cells
of the duodenal epithelium and in the uterus of
pregnant women, but it is now established that it is
generally present in all those tissues that deliver iron in
the plasma, including macrophages where it plays a
prominent role in iron egress (Ward and Kaplan 2012
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and refs therein). Ferroxidases such as the blue
multicopper oxidase ceruloplasmin collaborate with
ferroportin for efficient export of iron from cells
(Musci et al. 2014), facilitating incorporation of
ferrous iron transported through ferroportin as ferric
iron in an extracellular acceptor. Two isoforms of
ceruloplasmin are found in mammals: secreted ceru-
loplasmin is mainly synthesized by hepatocytes and
released into the plasma, while a GPI-anchored form
produced by alternative splicing has been identified in
numerous tissues, including macrophages and
immune cells (Musci et al. 2014 and refs therein).
Ceruloplasmin has been recognized to be an acute
phase protein many years ago and it is induced in
response to pro-inflammatory stimuli, such as IL-1b
(Barber and Cousins 1988; Persichini et al. 2010) and
IFN-c (Mazumder et al. 1997).
Ferroportin expression is regulated at multiple
levels and by multiple factors. In particular, ferropor-
tin is down-regulated at the transcriptional level by
pro-inflammatory cytokines in reticuloendothelial
cells, as demonstrated by the finding that treatment
with IFN-c and LPS reduced ferroportin mRNA and
iron release from monocytes (Ludwiczek et al. 2003;
Yang et al. 2002). Ferroportin mRNA and protein was
also found to decrease significantly in astrocytes
treated with LPS but not with IL-6 or TNF-a (Urrutia
et al. 2013). Interestingly, we have found that in rat C6
glioma cells ceruloplasmin and ferroportin are both
up-regulated by IL-1b, suggesting that the response of
ferroportin to cytokines might be tissue-specific
(Bonaccorsi di Patti et al. 2004; Persichini et al. 2010).
The amount of ferroportin at the plasma membrane
is post-translationally regulated by binding of the
peptide hepcidin, which induces internalization and
lysosomal degradation of ferroportin, leading to
decreased export of iron from cells (Nemeth et al.
2004). In turn, hepcidin synthesis is up-regulated in
response to iron loading, LPS and inflammation and it
is suppressed by anemia and hypoxia (Ganz 2013).
Thus, increased hepcidin levels in response to inflam-
mation result in decreased iron export and macrophage
iron retention. Hepcidin is synthesized mainly in the
liver; however, it has been demonstrated that in human
monocytes and in THP-1 cells LPS and IL-6 induce
hepcidin mRNA which in turn causes degradation of
ferroportin in an autocrine fashion, leading to intra-
cellular iron retention and contributing to the anemia of
inflammation (Theurl et al. 2008).
Lack of ferroxidase activity in specific cell types
(including macrophages) also leads to degradation of
ferroportin (De Domenico et al. 2007), demonstrating
that multiple mechanisms act to control iron balance
mediated by the transport activity of ferroportin.
Lactoferrin, a glycoprotein able to reversibly che-
late two Fe3? per molecule with high affinity, ensures
that the proper 10-18 M free iron concentration in
human fluids is maintained, thus avoiding iron
precipitation, reactive oxygen species formation and
microbial colonization (Legrand et al. 2008). Lacto-
ferrin is a multi-functional protein whose activities are
both dependent and independent of its iron-binding
ability. Lactoferrin is synthesized by exocrine glands
and neutrophils in infection and inflammation sites
and it is endowed with a potent immuno-modulating
and anti-inflammatory activity, which contributes to
protect mucosa from infections and inflammation
(Legrand et al. 2005; Puddu et al. 2009). Although the
mechanisms underlying these properties have not been
fully elucidated, evidences indicate that lactoferrin
acts both at the cellular level by modulating migration
and cell activation, and, at the molecular level, by
affecting expression of cytokines, chemokines and
other effector molecules, thus contributing to the
regulation of inflammation (Puddu et al. 2012).
In this work we have investigated the role of
lactoferrin on the expression of ferroportin in THP-1
cells challenged with LPS, a condition that mimics
exposure to pathogens or inflammation. Our results
indicate that bovine lactoferrin can counteract the
decrease of ferroportin protein induced by LPS. We
show that this effect is related to reduction of IL-6
secretion by THP-1 cells.
Materials and methods
Materials
Highly purified bovine milk derivative lactoferrin
(bLf) was kindly provided by Morinaga Milk Indus-
tries Co., Ltd. (Tokyo, Japan). LPS contamination of
bLf, estimated by Limulus Amebocyte assay (LAL
Pyrochrome kit, PBI International), was equal to
0.5 ± 0.06 ng/mg of bLf. The bLf iron saturation was
about 22 %. Before biological assays bLf was steril-
ized by filtration (Millipore).
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Cell culture and treatments
THP-1 human acute monocytic leukemia cells
(ECACC, European Collection of Cell Cultures) were
maintained in RPMI 1640 medium (Euroclone) sup-
plemented with 10 % fetal calf serum, 100 lM
penicillin–streptomycin and 2 mM glutamine in an
atmosphere of 95 % air and 5 % CO2. Undifferenti-
ated cells which grow spontaneously in loose suspen-
sion under these conditions were subcultured every
3 day by gentle shaking followed by pelleting and
reseeding at a density of approximately 106 cells per
ml. THP-1 cells were differentiated by incubation with
0.16 lM phorbol myristate acetate (PMA, Sigma) for
48 h at 37 C (Scorneaux et al. 1996). Monocytes and
differentiated THP-1 cells were stimulated with 1 lg/
ml LPS from E. coli (InvivoGen) for 24 and 48 h;
100 lg/ml bLf was added to monocytes or adherent
THP-1 cells without removing the culture medium
after 3 and 24 h of stimulation with LPS and/or 2 lg/
ml hepcidin-25 (Bachem). Afterwards, the cell were
recovered and the supernatants were harvested and
stored at -80 C for quantification of cytokines; the
pellets were suspended in PBS containing PMSF
1 mM, centrifuged at 2,5009g for 5 min and stored at
-80 C for evaluation of ferroportin expression by
western blot.
IL-6 analysis
IL-6 concentration in culture media was measured by
ELISA using Human IL-6 ELISA Max Deluxe Set
(BioLegend).
Western blot analysis
THP-1 cells (5 9 106–1 9 107 cells) were lysed in
300 ll MOPS 25 mM pH 7.4/NaCl 150 mM/Triton
1 % containing PMSF 1 mM, leupeptin and pepstatin
2 lM in ice for 1 h. Total protein content of samples
was measured by the Bradford assay. For SDS-PAGE
20 lg of total protein were loaded per lane, for
ferroportin analysis SDS sample buffer containing
DTT was added and samples were loaded without heat
treatment. For western blot analysis, primary antibodies
used were: monoclonal anti-ferroportin 31A5 (Amgen,
described in Ross et al. 2012) (1:10,000) and monoclo-
nal anti-actin (BD) (1:10,000). After incubation with the
appropriate secondary HRP-conjugated antibody, blots
were developed with ECL Prime (GE Healthcare).
Ferroportin levels were normalized on actin by densi-
tometry analysis, performed with ImageJ.
Ferritin analysis
Intracellular ferritin content was measured by ELISA
(Human Ferritin Kit, Abnova), according to the
manufacturer’s instructions.
Results
To assess the effect of lactoferrin on LPS-induced
inflammation in human monocytes we stimulated
undifferentiated THP-1 cells with three different
concentrations of E. coli LPS (0.01, 0.1 and 1 lg/ml)
in the absence and presence of bLf at 100 lg/ml for
24 h. As shown in Fig. 1, bLf was able to reduce IL-6
production at higher LPS concentrations, the effect
being evident already on cells treated with 0.1 lg/ml
LPS, with a reduction of about 15 %, and more notable
at 1 lg/ml LPS with a ca. 30 % reduction of IL-6
production. Therefore, the latter concentration of LPS
was chosen for all further experiments.
Effect of lactoferrin on IL-6 and ferroportin
expression in undifferentiated THP-1 cells
To investigate the effect of lactoferrin on LPS-induced
inflammation and iron homeostasis, undifferentiated
THP-1 cells were stimulated with 1 lg/ml LPS in the
Fig. 1 IL-6 production by monocytic THP-1 cells. Cells were
stimulated for 24 h with three different concentration of E. coli
LPS (0.01, 0.1 and 1 lg/ml), in the presence or absence of
100 lg/ml bLf (added after 3 h of LPS treatment). IL-6 levels
were measured by ELISA on culture media
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presence and absence of 100 lg/ml bLf. Production of
IL-6 and expression of the iron exporter ferroportin
was assessed. Lactoferrin was added after 3 h of
incubation with LPS, a second addition of bLf was
carried out after 24 h to ensure that adequate levels of
the iron protein were maintained in the culture
medium. We performed the experiment in the pre-
sence or absence of hepcidin to further evaluate the
role of this peptide in the modulation of ferroportin
levels.
The results were significantly reproducible for IL-6,
showing the expected large increase of the interleukin
levels upon stimulation with LPS and a partial, yet
significant decrease in the presence of lactoferrin, as
reported in Fig. 1. On the other hand, results were
highly variable when ferroportin was considered.
Figure 2 reports IL-6 and ferroportin levels measured
in two independent experiments. As can be seen, the
reproducible increase of IL-6 levels, and the counter-
acting effect of bLf, could not be related to reproduc-
ible variations of ferroportin levels, which were
usually not affected (or even increased) by LPS
(Fig. 2a), although in some isolated experiments (like
the one in Fig. 2b) the protein levels of the iron
exporter were severely impaired upon LPS stimula-
tion. In this latter case, however, lactoferrin exerted a
rescuing effect, with ferroportin levels going back to
normal in its presence.
Hepcidin was found to not affect the LPS-induced
IL-6 increase. Treatment with hepcidin, on the other
hand, induced a marked reduction in ferroportin
protein of about 40 % in all conditions, indicating
that, as expected, the immunoreactive band for
ferroportin is hepcidin-sensitive (data not shown).
We also measured intracellular ferritin expression
by ELISA. In line with the results obtained on
ferroportin, ferritin was generally not influenced by
LPS and bLf, nor by the presence of hepcidin, as
representatively shown in Fig. 2c. Regarding this
latter point, it is likely that, in our experimental
conditions, the hepcidin-induced decrease of ferro-
portin was not sufficient to increase intracellular iron
levels enough to stimulate ferritin synthesis.
Effect of lactoferrin on IL-6 and ferroportin
expression in differentiated THP-1 cells
To investigate the role of differentiation in the
response of THP-1 cells to inflammation, cells were
treated with PMA and differentiated in adherent
mature macrophages. First, we analysed whether
ferroportin levels were affected by differentiation.
To this end, cells were differentiated with PMA for
48 h and then further incubated for 24 or 48 h in the
absence or presence of lactoferrin. As shown in
Fig. 3a, ferroportin increased ca. twofold after PMA-
induced differentiation. Lactoferrin further affected
Fig. 2 Expression of ferroportin and ferritin by monocytic
THP-1 cells. THP-1 cells were treated for 48 h with 1 lg/ml
E. coli LPS in the presence or absence of 100 lg/ml bLf (added
after 3 and 24 h of LPS treatment). a, b Western blot
densitometry analysis of ferroportin levels of two different
experiments. c intracellular ferritin levels measured by ELISA
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ferroportin levels, the effect being already evident at
24 h and more evident at 48 h of incubation with a ca.
20 % increase (Fig. 3a). This finding may be related to
the iron carrier properties of lactoferrin, as iron
released from the protein might lead to induction of
ferroportin synthesis to cope with the increased metal
load within the cell.
We then tested the response of THP-1 mature cells
to LPS in the absence and presence of lactoferrin in
terms of IL-6 production and ferroportin expression. At
variance with the parallel experiments carried out on
undifferentiated cells (see Fig. 2), results were quite
reproducible on differentiated macrophages. Again,
we show here representative experiments. As reported
in Fig. 3b, the ELISA run on secreted IL-6 indicated
that differentiated macrophages respond to the LPS
treatment with a ca. twofold higher production of the
cytokine compared to undifferentiated monocytes.
Lactoferrin treatment significantly reduced LPS-
triggered IL-6 secretion by about 60 %, indicating a
much higher efficiency in comparison to that exerted
on monocytes.
Quite interestingly, densitometric analysis of the
Western blot on ferroportin showed that the protein
levels were significantly reduced by LPS treatment
and that bLf significantly reversed this effect, bringing
back ferroportin expression close to that of untreated
cells (Fig. 3c). The effect was already evident after
24 h of treatment and clearly observable after 48 h,
when the protein expression levels in LPS-treated cells
were about 30 % lower than those of control cells, and
lactoferrin fully restored ferroportin levels.
Ferritin ELISA analysis again did not show signif-
icant differences between samples (Fig. 3d). However,
as observed for ferroportin, ferritin expression levels
were significantly different from those of undifferen-
tiated cells. In particular, ferritin was about twofold
lower in mature macrophages that in undifferentiated
Fig. 3 Expression of IL-6, ferroportin and ferritin by adherent
macrophagic THP-1 cells. THP-1 cells were stimulated for 48 h
with 0.16 lM PMA until differentiation and adhesion. Adherent
cells were treated for 24 and 48 h with 1 lg/ml E. coli LPS in the
presence or absence of 100 lg/ml bLf (added after 3 and 24 h of
LPS treatment). a Western blot densitometry analysis of
ferroportin on adherent cells compared to undifferentiated
THP-1 cells. Cells were differentiated with PMA for 48 h and
then further incubated for 24 or 48 h in the absence or presence
of lactoferrin. b IL-6 production by adherent THP-1 cells after
48 h. c Western blot densitometry analysis of ferroportin on
adherent THP-1 cells. d intracellular ferritin levels measured by
ELISA
Biometals (2014) 27:807–813 811
123
THP-1 cells (cf. Figs. 2c, 3d). This result is in line with
the higher iron export ability of these cells, i.e. with
their higher ferroportin expression.
Discussion
Macrophages play a key role in iron homeostasis,
through their ability to scavenge senescent and
damaged erythrocytes, recycling iron recovered from
hemoglobin. Iron and immunity are tightly linked and
many studies have addressed the relationships
between iron management by macrophages, the ability
of these cells to cope with invading pathogens and
inflammation, and the effect of different molecules
that can modulate the expression of proteins involved
in iron homeostasis in macrophages. Leukemic cell
lines such as THP-1 promonocytes are widely used as
a model for human monocytes. The transition of
normal state circulating monocytes to adherent cyto-
kine-producing inflammatory cells is a step of critical
importance in the development of the response to
pathogens or inflammation. Biomolecules that can
modulate this transition can be viewed as potential
therapeutic agents for control of these processes.
Lactoferrin has been shown to possess potent antibac-
terial and anti-inflammatory properties. Previous
studies showed that lactoferrin added before treatment
with LPS blunted the IL-6 response of THP-1 cells
primed with IFN-c, possibly by interfering with NF-
jB signaling (Haversen et al. 2002). Here we show
that a similar effect of lactoferrin is obtained in THP-1
cells primed with PMA before stimulation with LPS.
Exposure of the cells to a priming agent potentiates the
response to subsequent stimuli, and in line with this
observation we see a much more effective action of
lactoferrin on cells treated with PMA than on undif-
ferentiated cells.
It is known that ferroportin expression is regulated
at multiple levels and by multiple factors. In partic-
ular, previous studies have shown that ferroportin is
down-regulated at the transcriptional level by pro-
inflammatory cytokines in reticuloendothelial cells, as
demonstrated by the finding that treatment with IFN-c
and LPS reduced ferroportin mRNA and iron release
from monocytes (Ludwiczek et al. 2003; Yang et al.
2002). Ferroportin mRNA and protein was also found
to decrease significantly in astrocytes treated with LPS
but not with IL-6 or TNF-a (Urrutia et al. 2013). Our
data are consistent with these findings, moreover we
could demonstrate that downregulation of ferroportin
can be reverted by the iron protein lactoferrrin playing
an anti-inflammatory role. Interestingly, we have also
found that in rat C6 glioma cells ceruloplasmin and
ferroportin are both up-regulated by IL-1b (Bonac-
corsi di Patti et al. 2004; Persichini et al. 2010),
suggesting that the response of ferroportin to cytokines
might be tissue-specific.
Stimulation with LPS and IL-6 production have
been shown to result in increased expression of
hepcidin mRNA in human monocytes and THP-1
cells. In turn, this leads to increased hepcidin-depen-
dent degradation of ferroportin and consequently to
iron retention in these cells (Theurl et al. 2008). We
therefore propose that lactoferrin prevents the
decrease of ferroportin levels in THP-1 cells stimu-
lated with LPS because it reduces the LPS- and/or IL-
6-dependent induction of hepcidin.
Of note, the expression of ferroportin appeared to
be higher in adherent PMA-treated THP-1 cells
compared to undifferentiated monocytic cells. Most
of the proteins involved in cellular iron homeostasis
appear to be differentially expressed in polarized
macrophages. Different groups have reported that
in vitro polarized murine and human M1 inflammatory
macrophages present a ‘storage’ phenotype while M2
tolerogenic macrophages have effective iron-recy-
cling capacity (Corna et al. 2010; Recalcati et al.
2010). In fact, M1 (IFN-c/LPS) macrophages were
found to exhibit high levels of ferritin H and low levels
of ferroportin, CD163, TfR1 and HO-1; M2 (IL-4)
macrophages instead presented high levels of CD163,
TfR1, ferroportin, HO-1, and low levels of ferritin H.
Ceruloplasmin and hepcidin were found to be
expressed at higher levels in M1 macrophages.
Possible explanations for the different iron manage-
ment by M1 and M2 macrophages are linked to their
different physiological roles, whereby inflammatory
M1 macrophages must cope with invading intracellu-
lar pathogens and therefore must sequester iron.
Tolerogenic M2 macrophages, on the other hand, are
involved in tissue repair and it has been suggested that
their lower iron retaining capacity might impact
cytokine production and/or it may affect other cells
in the microenvironment (Cairo et al. 2011; Recalcati
et al. 2010).
In conclusion, our results demonstrate that lacto-
ferrin can counteract the LPS-induced decrease of
812 Biometals (2014) 27:807–813
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ferroportin protein levels in adherent macrophage
THP-1 cells by lowering IL-6 production. Restoring
ferroportin at the plasma membrane will affect the iron
export ability of these cells with possible beneficial
effects, contrasting the anemia of inflammation. Our
finding may also have implications in the response of
inflammatory macrophages to challenges and confirms
once again the tight connection between iron homeo-
stasis and inflammation.
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